ClinicalTrials.gg
CompletedNCT07104461APPETITEUpdated Aug 21, 2025

Advanced Protein-based Program for Effective Treatment of Appetite Regulation and Obesity

An interventional study of Oat porridge and Whey protein isolate in Appetite and General Nutritional Disorders, sponsored by University of Westminster. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by University of Westminster · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Jun 2023, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Insulin Resistance with a site in United Kingdom — 7 open to participants now, 9 under way, none of them phase 3. Insulin Resistance · United Kingdom.

Enrollment
74th of 95
12 · median 31
Started
2023
with 1 other
No phase
76 of 106
4 open now
Registered
103rd of 106
by date

Among the 106 studies in Insulin Resistance with a site in United Kingdom, this one is the 74th largest by enrollment of the 95 interventional ones that give a count, is one of 2 that started in 2023, is one of 76 with no phase, and was the 103rd registered.

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

7 of the 106 studies in Insulin Resistance with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Insulin Resistance with a site in United Kingdom, or all of them as a file.
02

Study summary

INTRODUCTION: Obesity is a global epidemic, with over 2.5 billion adults being classified as overweight and 890 million of these classified as obese. Overweight and obesity are the 5th cause of mortality globally, with an estimated 2.8 million related deaths among adults. The rising prevalence of obesity in adults is leading to a rise in the prevalence of type 2 diabetes, with an estimated 462 million individuals affected globally. At present, the most effective non-surgical obesity treatments offered by the National Health Service (NHS) are the subcutaneously administered GLP-1 receptor agonists. However, they may present potentially serious side effects following short-term use, and there are still uncertainties around long-term use side effects. Therefore, a dietary approach to weight loss or maintenance seems preferable.

Increasing protein intake is a commonly applied nutritional approach to appetite regulation. The increase in protein intake is often achieved by supplementation, using proteins isolated from dairy, such as whey and casein. However, with more individuals following plant-based diets over recent years, the interest in plant-based protein supplements has increased. While dairy-based proteins are well-characterised, the appetite regulatory characteristics of plant-based proteins have not yet been fully elucidated.

The main aim of this study is to investigate the effects of protein-enriched food items on appetite regulation compared to a standard carbohydrate-rich meal. Furthermore, this study will investigate whether there are any differences in appetite-related hormonal responses to a plant protein-containing meal replacement shake (containing rice and pea protein) or a potato protein-enriched standard carbohydrate-based meal compared to a whey protein-enriched standard carbohydrate-based meal.

Read the detailed description

Intervention study with four treatment groups in a randomised, single-blind, quadruple crossover design.

Healthy male participants (between the ages of 18 to 50 years) will receive four different isocaloric intervention meals with the same mass, on separate visit days, following a minimum of 8 hours overnight fast. The four meals will contain oat porridge prepared with coconut milk as a control, oat porridge prepared with coconut milk with added whey or potato protein isolates, and a complete meal replacement shake containing plant-based pea and rice proteins. The intervention meals will be followed by a standardised pasta-based ready meal after the 3-hour observation period. All participants will observe at least a two-day washout period between the differing treatments.

Biological samples (blood) will be collected at various times during the visit. Blood samples will be collected at baseline 0 min prior (T0), then at 30 min (T30), 60 min (T60), 120 min (T120) and 180 min (T180) after the intervention meal consumption.

In addition, pertinent questionnaires, Visual Analogue Scale [VAS] for assessing satiety and VAS for assessing intervention meals' perception and palatability will be collected. VAS for the assessment of satiety will be collected at T0, T30, T60, T120 and T180 and VAS assessing the perception and palatability of the intervention meals will be collected immediately following meal consumption.

03

Conditions studied

  • Appetite and General Nutritional Disorders

Browse trials for

Keywords

  • nutraceutical
  • protein
  • whey
  • potato protein
  • rice protein
  • pea protein
  • appetite
  • satiety
  • insulin
  • glucose
  • ghrelin
  • appetite hormone
  • GLP-1
  • PYY
  • GIP
  • supplement
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males (18-50 years of age)
  • Lean and Overweight subjects ( 18.5 - 30 kg/m2)
  • Sedentary and physically active subjects
  • Healthy subjects

Exclusion criteria

Exclusion Criteria:

  • Female
  • \<18, >50 years
  • Dieting
  • Consumption of >14 units of alcohol/week
  • Allergies to test foods/drinks
  • Illnesses or on medication (with a possible effect on taste and/or appetite)
  • Devices such as pacemakers
  • Smokers
  • Gastrointestinal disorders
  • Eating disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
12 participants (actual)

Study arms

  • Sham comparator
    Oat porridge

    Control Meal (9.5 g total protein)

    Other: Oat porridge

  • Active comparator
    Oat porridge with whey protein

    (total protein 40.5 g; of which whey protein isolate contributed 34.2 g of protein)

    Dietary Supplement: Whey protein isolate

  • Active comparator
    Oat porridge with potato protein

    (total protein 40.6 g; of which potato protein isolate contributed 34.39 g of protein)

    Dietary Supplement: Potato protein isolate

  • Active comparator
    Meal replacement shake

    (total protein 40 g, mostly from pea protein and brown rice protein isolates)

    Dietary Supplement: Meal replacement shake

Interventions

  • OtherOat porridge

    Oat flakes, 81g (equivalent to 9 g of protein), were presented to participants in the form of porridge, prepared with 500 mL coconut milk (equivalent to 0.5 g of protein) and 10 g of zero calorie sugar free syrup. The total energy content was equivalent to 400 Kcal. Participants were instructed to consume the entire meal presented to them in 15 minutes on an empty stomach when attending the study.

  • Dietary supplementWhey protein isolate

    Whey protein isolate, 38g (equivalent to 34.2 g of protein), was presented to participants in the form of a porridge. Other ingredients in the whey protein enriched porridge: * Oat flakes 54 g (equivalent to 6 g of protein) * Coconut milk 300 mL (equivalent to 0.3 g of protein) * Water 150 mL * Zero calorie sugar free syrup 10 g The total energy content was equivalent to 401.74 Kcal. Participants were instructed to consume the entire meal presented to them in 15 minutes on an empty stomach when attending the study

  • Dietary supplementPotato protein isolate

    Potato protein isolate, 38g (equivalent to 34.39 g of protein), was presented to participants in the form of a porridge. Other ingredients in the potato protein enriched porridge: * Oat flakes 54 g (equivalent to 6 g of protein) * Coconut milk 300 mL (equivalent to 0.3 g of protein) * Water 150 mL * Zero calorie sugar free syrup 10 g The total energy content equiv. 401.36 Kcal. Participants were instructed to consume the entire meal presented to them in 15 minutes on an empty stomach when attending the study.

  • Dietary supplementMeal replacement shake

    A meal replacement, 90 g (equivalent to 40 g of total protein), was presented to participants in the form of a shake. Other ingredients in the meal replacement shake: \- Water 500 mL The total energy was equivalent to 400 Kcal Participants were instructed to consume the entire meal replacement shake presented to them in 15 minutes on an empty stomach when attending the study.

06

What researchers measure

Primary outcomes

  1. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate and meal replacement shake on glucose levels (T30)

    Glucose (mmol/L)

    Time frame: Glucose measured 30 minutes post meal consumption

  2. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucose levels (T60)

    Glucose (mmol/L)

    Time frame: Glucose measured 60 minutes post meal consumption

  3. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucose levels (T120)

    Glucose (mmol/L)

    Time frame: Glucose measured 120 minutes post meal consumption

  4. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucose levels (T180)

    Glucose (mmol/L)

    Time frame: Glucose measured 180 minutes post meal consumption

  5. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on insulin levels (T30)

    Insulin (pmol/L)

    Time frame: Insulin measured 30 minutes post meal consumption

  6. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on insulin levels (T60)

    Insulin (pmol/L)

    Time frame: Insulin measured 160 minutes post meal consumption

  7. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on insulin levels (T120)

    Insulin (pmol/L)

    Time frame: Insulin measured 120 minutes post meal consumption

  8. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on insulin levels (T180)

    Insulin (pmol/L)

    Time frame: Insulin measured 180 minutes post meal consumption

  9. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucagon-like peptide 1 levels (T30)

    Glucagon-like peptide 1 (pmol/L)

    Time frame: Glucagon-like peptide 1 measured 30 minutes post meal consumption

  10. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucagon-like peptide 1 levels (T60)

    Glucagon-like peptide 1 (pmol/L)

    Time frame: Glucagon-like peptide 1 measured 60 minutes post meal consumption

  11. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucagon-like peptide 1 levels (T120)

    Glucagon-like peptide 1 (pmol/L)

    Time frame: Glucagon-like peptide 1 measured 120 minutes post meal consumption

  12. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on glucagon-like peptide 1 levels (T180)

    Glucagon-like peptide 1 (pmol/L)

    Time frame: Glucagon-like peptide 1 measured 180 minutes post meal consumption

  13. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on gastric inhibitory polypeptide (T30)

    Glucagon-like peptide 1 (pmol/L)

    Time frame: Gastric inhibitory polypeptide measured 30 minutes post meal consumption

  14. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on gastric inhibitory polypeptide (T60)

    Glucagon-like peptide 1 (pmol/L)

    Time frame: Gastric inhibitory polypeptide measured 60 minutes post meal consumption

  15. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on gastric inhibitory polypeptide (T120)

    Glucagon-like peptide 1 (pmol/L)

    Time frame: Gastric inhibitory polypeptide measured 120 minutes post meal consumption

  16. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on gastric inhibitory polypeptide (T180)

    Glucagon-like peptide 1 (pmol/L)

    Time frame: Gastric inhibitory polypeptide measured 180 minutes post meal consumption

  17. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on peptide tyrosine tyrosine levels (T30)

    Peptide tyrosine tyrosine (pmol/L)

    Time frame: Peptide tyrosine tyrosine measured 30 minutes post meal consumption

  18. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on peptide tyrosine tyrosine levels (T60) Markers: peptide tyrosine tyrosine (pmol/L)

    Peptide tyrosine tyrosine (pmol/L)

    Time frame: Peptide tyrosine tyrosine measured 60 minutes post meal consumption

  19. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on peptide tyrosine tyrosine levels (T120)

    Peptide tyrosine tyrosine (pmol/L)

    Time frame: Peptide tyrosine tyrosine measured 120 minutes post meal consumption

  20. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on peptide tyrosine tyrosine levels (T180)

    Peptide tyrosine tyrosine (pmol/L)

    Time frame: Peptide tyrosine tyrosine measured 180 minutes post meal consumption

  21. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on ghrelin levels (T30)

    Ghrelin (pmol/L)

    Time frame: Ghrelin measured 30 minutes post meal consumption

  22. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on ghrelin levels (T60)

    Ghrelin (pmol/L)

    Time frame: Ghrelin measured 60 minutes post meal consumption

  23. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on ghrelin levels (T120)

    Ghrelin (pmol/L)

    Time frame: Ghrelin measured 120 minutes post meal consumption

  24. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on ghrelin levels (T180)

    Ghrelin (pmol/L)

    Time frame: Ghrelin measured 180 minutes post meal consumption

  25. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on appetite (T30)

    Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score, the greater the level of appetite)

    Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 30 minutes after meal consumption

  26. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on appetite (T60)

    Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score, the greater the level of appetite)

    Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 60 minutes after meal consumption

  27. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on appetite (T120)

    Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score, the greater the level of appetite)

    Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 120 minutes after meal consumption

  28. To assess the acute effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on appetite (T180)

    Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score, the greater the level of appetite)

    Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 180 minutes after meal consumption

Secondary outcomes

  1. To assess the perception of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake. Subjective analysis including Visual Analogue Scale for Perception and Palatability (VAS-P).

    Scores range from 0 to 100 (the higher the score, the lower the palatability)

    Time frame: VAS for Perception and Palatability collected immediately after meal consumption

  2. To assess the effects of oat porridge, whey protein isolate, potato protein isolate, and meal replacement shake on food intake ad libitum, 3 hours after the intervention meal consumption.

    Consecutive meal intake was assessed by measuring the weight in grams and calculating the energy content in Kcal of the food consumed.

    Time frame: Ad libitum food intake was assessed 3 hours post breakfast intervention meal consumption

07

Study locations

1 site
  • Centre for Nutraceuticals School of Life Sciences, University of Westminster
    London, W1W 6UW, United Kingdom
08

References and documents

Publications

  • Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020 Mar;10(1):107-111. doi: 10.2991/jegh.k.191028.001. PubMed 32175717 ↗
  • Guo H, Guo Q, Li Z, Wang Z. Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis. Front Pharmacol. 2024 Nov 13;15:1461398. doi: 10.3389/fphar.2024.1461398. eCollection 2024. PubMed 39605914 ↗
  • Ismail I, Hwang YH, Joo ST. Meat analog as future food: a review. J Anim Sci Technol. 2020 Mar;62(2):111-120. doi: 10.5187/jast.2020.62.2.111. Epub 2020 Mar 31. PubMed 32292920 ↗
  • Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, Mannucci E. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab. 2017 Sep;19(9):1233-1241. doi: 10.1111/dom.12926. Epub 2017 Jun 20. PubMed 28244632 ↗
  • Patel S. Emerging trends in nutraceutical applications of whey protein and its derivatives. J Food Sci Technol. 2015 Nov;52(11):6847-58. doi: 10.1007/s13197-015-1894-0. Epub 2015 Jun 9. PubMed 26884639 ↗
  • Santesso N, Akl EA, Bianchi M, Mente A, Mustafa R, Heels-Ansdell D, Schunemann HJ. Effects of higher- versus lower-protein diets on health outcomes: a systematic review and meta-analysis. Eur J Clin Nutr. 2012 Jul;66(7):780-8. doi: 10.1038/ejcn.2012.37. Epub 2012 Apr 18. PubMed 22510792 ↗
  • Zushin PH, Wu JC. Evaluating the benefits of the early use of GLP-1 receptor agonists. Lancet. 2025 Jan 18;405(10474):181-183. doi: 10.1016/S0140-6736(24)02255-4. Epub 2024 Nov 12. No abstract available. PubMed 39547251 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Oct 2024, 16 months.

Of 715 non-industry interventional studies with no phase under Insulin Resistance, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 16 months is below that.

Counting every sponsor, half of 755 studies reached it within 21 months; a quarter within 9 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 5, 2025
StartActual
Jun 9, 2023
Primary completionActual
Oct 31, 2024
CompletionActual
Oct 31, 2024
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07104461
Lead sponsor
University of Westminster
Responsible party
Mohammed Gulrez Zariwala (Professor of Translational Physiology, University of Westminster) — Principal investigator
First posted
Aug 5, 2025
Start date
Jun 9, 2023
Primary completion
Oct 31, 2024
Completion
Oct 31, 2024
Last update
Aug 21, 2025

Study contacts

Mohammed Gulrez Zariwala, PhD
principal investigator · University of Westminster

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Whey Protein Isolate

Start the discussion